SmithKline Beecham rotavirus vaccine
Phase II trial for rotavirus vaccine will be delayed until SmithKline gains a better understanding of the adverse event risks in light of Wyeth-Lederle's withdrawal of RotaShield following reports of intussusception, the company said. Merck reports its rotavirus vaccine program will remain unchanged. Wyeth-Lederle said it is planning to pursue a new rotavirus vaccine formulation
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth